

# Ulrich Laufs

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8435928/publications.pdf>

Version: 2024-02-01

104  
papers

16,469  
citations

94433

37  
h-index

30087

103  
g-index

112  
all docs

112  
docs citations

112  
times ranked

15697  
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia. <i>Clinical Research in Cardiology</i> , 2023, 112, 197-202.	3.3	11
2	Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C. <i>Clinical Research in Cardiology</i> , 2022, 111, 243-252.	3.3	32
3	Combination lipid-lowering therapy as first-line strategy in very high-risk patients. <i>European Heart Journal</i> , 2022, 43, 830-833.	2.2	92
4	NTa€proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials. <i>ESC Heart Failure</i> , 2022, 9, 100-109.	3.1	13
5	Travelling with heart failure: risk assessment and practical recommendations. <i>Nature Reviews Cardiology</i> , 2022, 19, 302-313.	13.7	7
6	Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. <i>European Heart Journal</i> , 2022, , .	2.2	1
7	Novel Nongenetic Murine Model of Hyperglycemia and Hyperlipidemia-Associated Aggravated Atherosclerosis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 813215.	2.4	7
8	Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2022, 16, 286-297.	1.5	20
9	Hypercoagulability Impairs Plaque Stability in Diabetes-Induced Atherosclerosis. <i>Nutrients</i> , 2022, 14, 1991.	4.1	1
10	Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany. <i>Journal of Human Hypertension</i> , 2021, 35, 903-911.	2.2	15
11	Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. <i>Journal of Hepatology</i> , 2021, 74, 156-167.	3.7	264
12	No effects of PCSK9-inhibitor treatment on spatial learning, locomotor activity, and novel object recognition in mice. <i>Behavioural Brain Research</i> , 2021, 396, 112875.	2.2	3
13	Heart failure, cognition, and brain damage. <i>European Heart Journal</i> , 2021, 42, 1579-1581.	2.2	10
14	Phosphodiesterases 2, 3 and 4 can decrease cardiac effects of H2-histamine-receptor activation in isolated atria of transgenic mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 1215-1229.	3.0	13
15	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021, 42, 1742-1756.	2.2	63
16	Analysis of left ventricular rotational deformation by 2D speckle tracking echocardiography: a feasibility study in athletes. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2369-2386.	1.5	3
17	Effects of selective heart rate reduction with ivabradine on LV function and central hemodynamics in patients with chronic coronary syndrome. <i>IJC Heart and Vasculature</i> , 2021, 34, 100757.	1.1	1
18	Impact of COVID-19 lockdown on endurance capacity of elite handball players. <i>Journal of Sports Medicine and Physical Fitness</i> , 2021, 61, 977-982.	0.7	34

#	ARTICLE	IF	CITATIONS
19	The evidence for pharmacist care in outpatients with heart failure: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2021, 8, 3566-3576.	3.1	20
20	Extracellular NLRP3 inflammasome particles are internalized by human coronary artery smooth muscle cells and induce pro-atherogenic effects. <i>Scientific Reports</i> , 2021, 11, 15156.	3.3	8
21	Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1493-1503.	1.9	17
22	Interdisciplinary Physician-Pharmacist Medication Review for Outpatients With Heart Failure: A Subanalysis of the PHARM-CHF Randomized Controlled Trial. <i>Frontiers in Pharmacology</i> , 2021, 12, 712490.	3.5	4
23	Guanidinylated Apolipoprotein C3 (ApoC3) Associates with Kidney and Vascular Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3146-3160.	6.1	16
24	Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study. <i>Atherosclerosis Plus</i> , 2021, 43, 24-30.	0.7	17
25	Obesity – An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances. <i>Biomolecules</i> , 2021, 11, 1426.	4.0	35
26	Interleukin-1 $\beta$ Is a Central Regulator of Leukocyte-Endothelial Adhesion in Myocardial Infarction and in Chronic Kidney Disease. <i>Circulation</i> , 2021, 144, 893-908.	1.6	36
27	Genetic Variation in Sodium-glucose Cotransporter 2 and Heart Failure. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 149-158.	4.7	11
28	Familial chylomicronemia syndrome due to a heterozygous deletion of the chromosome 8 treated with the apoCIII inhibitor volanesorsen. <i>Medicine (United States)</i> , 2021, 100, e27573.	1.0	1
29	Heart failure is independently associated with white matter lesions: insights from the population-based LIFE Adult Study. <i>ESC Heart Failure</i> , 2021, 8, 697-704.	3.1	16
30	Letter on “Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial”: reply. <i>European Journal of Heart Failure</i> , 2020, 22, 565-566.	7.1	1
31	Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 593-603.	1.8	224
32	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	2.2	4,871
33	Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. <i>Nature Immunology</i> , 2020, 21, 30-41.	14.5	169
34	Clinical review on triglycerides. <i>European Heart Journal</i> , 2020, 41, 99-109c.	2.2	286
35	Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2020, 14, 649-659.e6.	1.5	70
36	Speckle tracking echocardiography in a patient with viral myocarditis and acute myocardial infarction. <i>Journal of Cardiology Cases</i> , 2020, 22, 184-191.	0.5	8

#	ARTICLE	IF	CITATIONS
37	Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020, 5, 1124.	6.1	128
38	The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARMaCHF randomized controlled trial. <i>ESC Heart Failure</i> , 2020, 7, 3310-3319.	3.1	10
39	Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias. <i>Journal of the American College of Cardiology</i> , 2020, 76, 563-579.	2.8	52
40	Statin intolerance: myths and facts. <i>European Heart Journal</i> , 2020, 41, 3343-3345.	2.2	10
41	Coronary Balloon Angioplasty is due to two physicians born in Saxony, Germany. <i>European Heart Journal</i> , 2020, 41, 1462-1463.	2.2	0
42	Echocardiographic characteristics of patients with SARS-CoV-2 infection. <i>Clinical Research in Cardiology</i> , 2020, 109, 1549-1566.	3.3	61
43	PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects. <i>Frontiers in Physiology</i> , 2020, 11, 595819.	2.8	49
44	Angiography-based quantitative coronary contrast-flow ratio measurements correlate with myocardial ischemia assessed by stress MRI. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 1407-1416.	1.5	6
45	Possible new options and benefits to detect myocarditis, right ventricular remodeling and coronary anomalies by echocardiography in systematic preparticipation screening of athletes. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 1855-1885.	1.5	5
46	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	2.2	776
47	Effects of cardioselective beta-blockade on plasma catecholamines and performance during different forms of exercise. <i>Journal of Sports Medicine and Physical Fitness</i> , 2020, 60, 643-649.	0.7	3
48	The year in cardiology: cardiovascular prevention /The year in cardiology 2019. <i>Revista Romana De Cardiologie</i> , 2020, 30, 20-29.	0.1	0
49	Dear Doctor Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription. <i>Deutsches Arzteblatt International</i> , 2020, 117, 687-688.	0.9	2
50	Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 9-19.	1.8	15
51	Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice. <i>Scientific Reports</i> , 2019, 9, 11079.	3.3	29
52	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019, 290, 140-205.	0.8	1,753
53	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1381.	7.4	144
54	Association of Triglyceride-Lowering LPL Variants and LDL-C Lowering LDLR Variants With Risk of Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 364.	7.4	460

#	ARTICLE	IF	CITATIONS
55	Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARMaCHF randomized controlled trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1012-1021.	7.1	64
56	New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease. <i>Current Cardiology Reports</i> , 2019, 21, 69.	2.9	13
57	Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. <i>Journal of the American Heart Association</i> , 2019, 8, e011662.	3.7	292
58	Comparison of Different Strategies to Measure Medication Adherence via Claims Data in Patients With Chronic Heart Failure. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 211-218.	4.7	13
59	Effects of heart rate reduction with ivabradine on vascular stiffness and endothelial function in chronic stable coronary artery disease. <i>Journal of Hypertension</i> , 2019, 37, 1023-1031.	0.5	16
60	Why is hypercholesterolaemia so prevalent? A view from evolutionary medicine. <i>European Heart Journal</i> , 2019, 40, 2825-2830.	2.2	8
61	Analysis of regional right ventricular function by tissue doppler imaging in patients with aortic stenosis. <i>Journal of Cardiovascular Echography</i> , 2019, 29, 111.	0.4	6
62	Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. <i>Clinical Research in Cardiology</i> , 2018, 107, 380-388.	3.3	59
63	Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association. <i>European Journal of Heart Failure</i> , 2018, 20, 199-215.	7.1	128
64	Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018, 39, 2526-2539.	2.2	262
65	Effects of endurance training on serum lipids. <i>Vascular Pharmacology</i> , 2018, 101, 9-20.	2.1	38
66	Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry. <i>Atherosclerosis</i> , 2018, 277, 314-322.	0.8	27
67	Cardiac sarcoidosis: a challenging diagnosis. <i>Clinical Research in Cardiology</i> , 2018, 107, 980-986.	3.3	5
68	PHARMaCHF-based interdisciplinary program for patients with Chronic Heart Failure (PHARMaCHF): rationale and design of a randomized controlled trial, and results of the pilot study. <i>European Journal of Heart Failure</i> , 2018, 20, 1350-1359.	7.1	21
69	Pathological phenotypes of LDL particles. <i>European Heart Journal</i> , 2018, 39, 2574-2576.	2.2	15
70	Analysis of chronic aortic regurgitation by 2D and 3D echocardiography and cardiac MRI. <i>Journal of Animal Science and Technology</i> , 2018, 5, 51-62.	2.5	9
71	One-carbon metabolites and telomere length in a prospective and randomized study of B- and/or D-vitamin supplementation. <i>European Journal of Nutrition</i> , 2017, 56, 1887-1898.	3.9	25
72	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	2.2	2,292

#	ARTICLE	IF	CITATIONS
73	Vaccination to prevent atherosclerotic cardiovascular diseases. <i>European Heart Journal</i> , 2017, 38, 2508-2510.	2.2	12
74	<i>Primum non nocere</i>: the dangers of deferring heart failure therapy. <i>European Journal of Heart Failure</i> , 2017, 19, 1410-1411.	7.1	0
75	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 534-543.	11.4	84
76	HDL cholesterol: reappraisal of its clinical relevance. <i>Clinical Research in Cardiology</i> , 2017, 106, 663-675.	3.3	186
77	CaRe high â€“ Cascade screening and registry for high cholesterol in Germany. <i>Atherosclerosis Supplements</i> , 2017, 30, 72-76.	1.2	12
78	Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 947.	7.4	247
79	Leucocyte immunoglobulin-like receptor subfamily-B5 (LILRB5) genetic variation and statin-associated muscle symptoms: another piece in a puzzling puzzle. <i>European Heart Journal</i> , 2017, 38, 3576-3578.	2.2	9
80	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , 2016, 18, 672-683.	7.1	21
81	Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. <i>Clinical Research in Cardiology</i> , 2016, 105, 783-790.	3.3	43
82	Medication adherence and persistence according to different antihypertensive drug classes: A retrospective cohort study of 255,500 patients. <i>International Journal of Cardiology</i> , 2016, 220, 668-676.	1.7	69
83	LDL-Cholesterol: Standards of Treatment 2016: A German Perspective. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 323-336.	2.2	18
84	Evaluating patientsâ€™™ comprehensibility of a standardized medication plan. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1229-1237.	1.9	19
85	Resting heart rate is an independent predictor of all-cause mortality in the middle aged general population. <i>Clinical Research in Cardiology</i> , 2016, 105, 601-612.	3.3	26
86	Prospective study of telomere length and LINE-1 methylation in peripheral blood cells: the role of B vitamins supplementation. <i>European Journal of Nutrition</i> , 2016, 55, 1863-1873.	3.9	34
87	Statin intolerance. <i>Current Opinion in Lipidology</i> , 2015, 26, 492-501.	2.7	32
88	Treatment Options for Statin-Associated Muscle Symptoms. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2015, 112, 748-55.	0.9	65
89	Statin-associated muscle symptoms: impact on statin therapyâ€™™European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015, 36, 1012-1022.	2.2	1,024
90	Age-related medication adherence in patients with chronic heart failure: A systematic literature review. <i>International Journal of Cardiology</i> , 2015, 184, 728-735.	1.7	69

#	ARTICLE	IF	CITATIONS
91	Analyses of drugs stored at home by elderly patients with chronic heart failure. <i>Clinical Research in Cardiology</i> , 2015, 104, 320-327.	3.3	23
92	Exercise Promotes Collateral Artery Growth Mediated by Monocytic Nitric Oxide. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1862-1871.	2.4	32
93	New metrics needed to visualize the long-term impact of early LDL-C lowering on the cardiovascular disease trajectory. <i>Vascular Pharmacology</i> , 2015, 71, 37-39.	2.1	22
94	Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. <i>European Heart Journal</i> , 2015, 36, ehv352.	2.2	116
95	Moving beyond the "LDL hypothesis". <i>Vasa - European Journal of Vascular Medicine</i> , 2015, 44, 333-340.	1.4	12
96	Risk prediction with triglycerides in patients with stable coronary disease on statin treatment. <i>Clinical Research in Cardiology</i> , 2014, 103, 984-997.	3.3	10
97	Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1401-1408.	2.8	241
98	Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. <i>American Heart Journal</i> , 2013, 166, 306-314.e7.	2.7	51
99	Strategies to improve drug adherence. <i>European Heart Journal</i> , 2011, 32, 264-268.	2.2	87
100	ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload. <i>Cardiovascular Research</i> , 2009, 83, 106-114.	3.8	55
101	Suppression of Endothelial Nitric Oxide Production After Withdrawal of Statin Treatment Is Mediated by Negative Feedback Regulation of Rho GTPase Gene Transcription. <i>Circulation</i> , 2000, 102, 3104-3110.	1.6	274
102	Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice. <i>Stroke</i> , 2000, 31, 2442-2449.	2.0	359
103	Extracellular Inflammasome Particles Are Released After Marathon Running and Induce Proinflammatory Effects in Endothelial Cells. <i>Frontiers in Physiology</i> , 0, 13, .	2.8	3
104	Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012-2021. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	6